Investor Relations

Latest Financial Results

Q3 2019

Quarter Ended Jun 30, 2019

Latest Annual Filing

Fiscal Year Ended Sep 30, 2018

View Filing

Stock Information

Company Overview

Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.

CTXR Presentation_Fall 2019

CTXR Presentation_Fall 2019

Download CTXR Presentation_Fall 2019


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


Citius Pharmaceuticals, Inc.
11 Commerce Drive
First Floor
Cranford, NJ 07016
T: 908-967-6677

Investor Relations

Andrew Scott
VP of Investor Relations
T: 908-967-6677 ext. 105

Transfer Agent

VStock Transfer LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436